AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

RecruitingPhase 4Ages 18 Years - anyAllUniversity of California, Berkeley
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Is 18 years of age and has full legal capacity to volunteer (no max age requirement) * Baseline Ocular Surface Disease Index (OSDI) \>13 * Has mild to moderate MGD * Has best corrected visual acuity of 20/40 or better * Has had an oculo-visual examination in the last two years * Is willing to continue other daily dry eye management regimen (e.g., warm compresses, and/or eyelid margin cleaning) * Is willing to discontinue other prescription medications for dry eye disease (DED) management * Is willing to stop any topical eye drops before all planned visits * Has read, understood, and completed the informed consent letter Exclusion Criteria: * Is participating in any other type of clinical or research study * Is currently pregnant, nursing, lactating, or planning a pregnancy * Is currently having \>50% blockage of Meibomian glands in more than two eyelids or significant atrophy (i.e., severe MGD) * Is currently using any topical ocular medications * Has chronic or currently active sinus related problems * Has blepharitis \> grade 1 * Has active ocular infections * Has a condition or in a situation which, in the examiner's opinion, may put the subject at significant risk, may confound the study results, or may significantly interfere with their participation in the study * Has received Rx DED treatment within one week of enrollment * Has received any thermal or light-based DED treatment within 30 days of enrollment * Has significant corneal epithelial defects * Has abnormal eyelid anatomy * Has corneal neuropathic pain * Has chronic or recurrent epistaxis (nosebleeds), coagulation disorders, or other conditions that may have led to a clinically significant increased risk of bleeding * Has any intraocular surgery including trabeculectomy (MIGS, laser, or small incision glaucoma surgery allowed), extraocular surgery in either eye within 3 months, or refractive surgery within 12 months of enrollment * Has a known allergy to a product used in this study
๐Ÿ’Š

What it tests

  • Varenicline 0.03Mg/Spray Nasal Soln
๐Ÿ“

Where

1 site
U.C. Berkeley Clinical Research Center
Berkeley, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy